20 COMMERCE DRIVE, SUITE 135, CRANFORD, NJ
Enzon Pharmaceuticals Completes Exchange Offer for Series C Preferred Stock
Announces Reverse Stock Split
Enzon Pharmaceuticals Extends Exchange Offer for Series C Preferred Stock
Enzon Pharmaceuticals Enters Tenth Amendment to Section 382 Rights Agreement
Ninth Amendment to Section 382 Rights Agreement Executed by Enzon Pharmaceuti...
Eighth Amendment to Section 382 Rights Agreement Executed by Enzon Pharmaceut...
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2023
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Tender Offer Statement by Issuer
Amended Registration of Securities under Section 12(g)